Durability of Response |
Sirolimus only (N=4) |
Siro + Steroids (N=15) |
VCR only (N=5) |
VCR + Steroids (N=19) |
*p-value (steroid groups
only) |
Persistent disease 3 months from start of therapy, n (%) |
0 (0%) |
2
(13.3%) |
5 (100%) |
19 (100%) |
0.2 |
Persistent disease 6 months from start of therapy, n (%) |
0 (0%) |
3
(20%) |
0 (0%) |
1 (5.3%) |
0.3 |
Time to persistent disease from start of therapy (days), median
[IQR] |
1631.5 [977.3, 2285.8) |
257.5 [123.3, 551] |
NA |
407.5 [286.8, 528.3] |
0.8 |
Persistent disease requiring change in treatment agent, n (%) |
1
(25%) |
3 (20%) |
0 (0%) |
1 (5.3%) |
0.3 |
Persistent disease requiring continuation of current therapy, n (%) |
2
(50%) |
4 (26.7%) |
0 (0%) |
0 (0%) |
0.029 |
Recurrent disease 3 months from start of therapy, n (%) |
0 (0%) |
1
(6.7%) |
1 (20%) |
0 (0%) |
0.4 |
Recurrent disease 6 months from start of therapy, n (%) |
0 (0%) |
1
(6.7%) |
1 (20%) |
0 (0%) |
0.4 |
Time to recurrent disease from start of therapy (days), median [IQR] |
1915.5 [1509.8, 2321.3] |
430.5 [268.5,637.8] |
379 [193.5,
646] |
231 [231, 231] |
0.8 |
Recurrent disease requiring change in treatment agent, n (%) |
1 (25%) |
3 (20%) |
2 (40%) |
0 (0%) |
0.076 |
Recurrent disease requiring re-initiation of prior therapy, n (%) |
1
(25%) |
4 (26.7%) |
1 (20%) |
2 (10.5%) |
0.4 |
Progressive disease 3 months from start of therapy, n (%) |
0 (0%) |
1
(6.7%) |
0 (0%) |
0 (0%) |
0.4 |
Progressive disease 6 months from start of therapy, n (%) |
0 (0%) |
1
(6.7%) |
0 (0%) |
0 (0%) |
0.4 |
Time to progressive disease from start of therapy (days), median
[IQR] |
730 [730, 730] |
1700 [1700, 1700] |
NA |
553
[387, 719] |
0.7 |
Progressive disease requiring change in treatment agent, n (%) |
0
(0%) |
1 (6.7%) |
0 (0%) |
1 (5.3%) |
>0.9 |
Progressive disease requiring re-initiation of prior therapy, n (%) |
1
(25%) |
0 (0%) |
0 (0%) |
1 (5.3%) |
>0.9 |